Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: A report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

TY - JOUR

T1 - Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: A report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

AU - Sureda, Anna

AU - Carpenter, Paul A

AU - Bacigalupo, Andrea

AU - Bhatt, Vijaya Raj

AU - de la Fuente, Josu

AU - Ho, Aloysius

AU - Kean, Leslie

AU - Lee, Jong Wook

AU - Sánchez-Ortega, Isabel

AU - Savani, Bipin N

AU - Schetelig, Johannes

AU - Stadtmauer, Edward A

AU - Takahashi, Yoshiyuki

AU - Atsuta, Yoshiko

AU - Koreth, John

AU - Kröger, Nicolaus

AU - Ljungman, Per

AU - Okamoto, Shinichiro

AU - Popat, Uday

AU - Soiffer, Robert

AU - Stefanski, Heather E

AU - Kharfan-Dabaja, Mohamed A

N1 - © 2024. The Author(s).

PY - 2024/6

Y1 - 2024/6

N2 - Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to be curative in benign hematologic disorders such as aplastic anemia, sickle cell disease, and thalassemia, among others. Recently, the American Society for Transplantation and Cellular Therapy (ASTCT) published standardized definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism. To attempt broader international consensus, a panel of adult and pediatric physician transplant experts was assembled from European Society for Blood and Marrow Transplantation (EBMT), ASTCT, the Center for International Blood and Marrow Transplant Research (CIBMTR), and Asia-Pacific Blood and Marrow Transplantation (APBMT). Consensus was defined as ≥70% of voting members strongly agreeing or somewhat agreeing with a definition. With few exceptions, there was a consensus to endorse the prior ASTCT definitions. Importantly, we revised existing EBMT and CIBMTR data collection forms to align with these harmonized definitions that will facilitate research and international collaboration among transplant researchers and across transplant registries.

AB - Despite emergence of novel therapies to treat hematologic malignancies, allogeneic hematopoietic cell transplantation (allo-HCT) remains an essential treatment modality capable of curing these diseases. Allo-HCT has been also shown to be curative in benign hematologic disorders such as aplastic anemia, sickle cell disease, and thalassemia, among others. Recently, the American Society for Transplantation and Cellular Therapy (ASTCT) published standardized definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism. To attempt broader international consensus, a panel of adult and pediatric physician transplant experts was assembled from European Society for Blood and Marrow Transplantation (EBMT), ASTCT, the Center for International Blood and Marrow Transplant Research (CIBMTR), and Asia-Pacific Blood and Marrow Transplantation (APBMT). Consensus was defined as ≥70% of voting members strongly agreeing or somewhat agreeing with a definition. With few exceptions, there was a consensus to endorse the prior ASTCT definitions. Importantly, we revised existing EBMT and CIBMTR data collection forms to align with these harmonized definitions that will facilitate research and international collaboration among transplant researchers and across transplant registries.

U2 - 10.1038/s41409-024-02251-0

DO - 10.1038/s41409-024-02251-0

M3 - SCORING: Journal article

C2 - 38443706

VL - 59

SP - 832

EP - 837

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 6

ER -